Utilizing a Multi-gene Testing Approach to Identify Hereditary Pancreatic Cancer

Completed

Conditions studied: Pancreatic Ductal Adenocarcinoma

In brief

The primary objective of the study will be to estimate the prevalence of germline mutations in patients who present consecutively within 12 weeks of a confirmed diagnosis of pancreatic ductal adenocarcinoma.

Key facts

Study ID

NCT02790944

Run by

Ambry Genetics

People needed

300

Starts

2016-05-04

Expected to finish

2020-08-15

Last updated by the study team

2020-08-25

Who can join

Age: 18 and older, up to 89. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male and female patients between the ages of 18 and 89 years of age.
• Diagnosed within the previous 12 weeks with histologically or cytologically confirmed PDAC Stage I to IV.
• Ability of participant to understand and the willingness to sign a written informed consent document.
• Participant must agree to sample collection and genetic testing using the 32 gene test, CancerNextTM and allow the test result to be part of their medical record.

You may not qualify if…

• Diagnosed with intraductal papillary mucinous neoplasms, mucinous cystic neoplasms, pancreatic neuroendocrine tumors or dysplasia without PDAC.
• Diagnosed with PDAC more than 12 weeks before presenting to the clinical site.
• Patients meeting the above enrollment criteria who have had CancerNext performed previously.

Where it is running

• HonorHealth Research Institute — Scottsdale, Arizona, United States
• Beth Israel Deaconess Medical Center — Boston, Massachusetts, United States
• University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.